| Title | Consultation response to the National Institute for Health and Clinical Excellence on '(1) Proposed Health Technology Appraisal - Lapatinib for breast cancer (First line use in advanced or metastatic hormone-sensitive breast cancer) - draft remit and draft scope' and '(2) Proposed Health Technology Appraisal - Lapatinib for breast cancer (For use in women with previously treated, advanced or metastatic breast cancer) - draft remit and draft scope' |